Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Lexicon Pharmaceuticals reports strong Q4 performance and eyes growth

Lexicon Pharmaceuticals showcased promising drug candidates and financial stability in Q4 2022.
While facing challenges in revenue generation and expense management, the company is strategically positioned for growth.
Opportunities lie in commercial launches, Phase 3 advancements, and potential partnerships to drive future success.
Overall, Lexicon's focus on maximizing asset value and advancing key drugs positions them for long-term success in the pharmaceutical market.

Lexicon Pharmaceuticals reports robust Q1 performance and eyes market expansion

Lexicon Pharmaceuticals showcased strong financials, promising drug candidates, and strategic confidence in market success.
Challenges lie in market penetration strategies, FDA feedback, and successful commercialization amidst competition.
Opportunities abound with upcoming sotagliflozin launch, advancing LX9211, and leveraging unique data for growth.

Lexicon Pharmaceuticals reports strong Q2 earnings and advances key treatments

Lexicon Pharmaceuticals demonstrated financial stability and strategic progress in Q2 2023, supported by strong cash reserves and key regulatory milestones.
The company's focus on patient-centric initiatives and upcoming product launches positions it for sustained growth and market success.
Challenges in market penetration and revenue realization require targeted strategies, while opportunities in market expansion and pipeline development offer avenues for growth.
Overall, Lexicon Pharmaceuticals shows promise with a solid foundation for future success, driven by innovation and market-focused strategies.

Lexicon Pharmaceuticals reports Q3 loss, highlights INPEFA progress and global expansion

Lexicon Pharmaceuticals faces challenges in market access and inventory trends while capitalizing on opportunities through geographic expansion and potential partnerships. The company's financial performance in Q3 2023 showed increased expenses but progress in prescription demand for INPEFA.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 People NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 People

Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy

Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

THE WOODLANDS, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon's chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET.

Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference

Lexicon has not been lucky with the FDA. However, there are reasons, discussed below, which make me see a special situation here.

Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead

THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the treatment of heart failure. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

Athersys

Amicus Therapeutics

Moderna

Nanobiotix SA

United Therapeutics

Verrica Pharmaceuticals Inc

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorPlace.

7 Biotech Stocks With Key Catalysts for May

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2022 Results Conference Call May 5, 2022 8:00 AM ET Company Participants Charles Schultz - Investor Relations Lonnel Coats - President and Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JP Morgan Joseph Stringer - Needham & Company Operator Good morning. This is Jesse, and I will be your conference operator today.

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2022 Results - Earnings Call Transcript

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update

THE WOODLANDS, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET / 7:00 a.m. CT that day to discuss its financial and operating results and to provide a general business update.

Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022

Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and stroke with sotagliflozin treatment as compared to placebo Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and stroke with sotagliflozin treatment as compared to placebo

Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)

NEW YORK , March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ: LXRX).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX

Late-breaking clinical trial presentation by Deepak L. Bhatt, M.D., M.P.H., will describe new analysis of rates of CV death, myocardial infarction and stroke in the SCORED trial Late-breaking clinical trial presentation by Deepak L. Bhatt, M.D., M.P.H., will describe new analysis of rates of CV death, myocardial infarction and stroke in the SCORED trial

New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)

THE WOODLANDS, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150 million in borrowing capacity designed primarily to support commercial preparations and the potential launch of sotagliflozin in heart failure.

Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Lexicon investments or would like to inquire about potentially pursuing claims to recover your loss under the federal se

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) investors concerning the Company's possible violations of federal securities laws. On February 28, 2022, Lexicon issued a press release announcing the voluntary withdrawal of the Company's New Drug Application for its glucose regulation drug, sotagliflozin, in order to correct a technical issue with the submission that h

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2022, Lexicon issued a press release announcing the voluntary withdrawal of the Company's New Drug Application for its glucose regulation drug, sot

The Law Offices of Frank R. Cruz Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of Investors

The shares are reeling from disquieting news about the company's leading pipeline drug.

Why Lexicon Pharmaceuticals Was Plunging on Monday

Lexicon Pharmaceuticals, Inc.'s (LXRX) CEO Lonnel Coats on Q4 2021 Results - Earnings Call Transcript

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update

Resubmission to Correct Recently-Identified Technical Issue

Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has voluntarily withdrawn and planned near-term resubmission of the sotagliflozin U.S. application to correct a technical issue with the submission recently identified by the company.  Lexicon has notified the FDA about the issue and.

Lexicon Pharma Pulls Sotagliflozin US Application Due To Technical Issue, Shares Fall

﻿THE WOODLANDS, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss its financial and operating results and to provide a general business update.

Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022

NDA submitted for sotagliflozin in heart failure with an expected launch in 2H 2022, if approved

Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference

THE WOODLANDS, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon's chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET.

Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.

News for Lexicon Pharmaceuticals Stock (LXRX)